- Conditions
- Pancreatic Neoplasms
- Interventions
- Heckel Infrared Radiant Heat Device, cisplatin, gemcitabine, interferon-alpha, thermochemotherapy
- Device · Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 161
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C, Hepatitis
- Interventions
- Merimepodib, PEG-Interferon-alpha 2a (Pegasys®), Ribavirin (Copegus®)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 55 more
- Conditions
- Hepatitis C Virus
- Interventions
- Pegylated-Interferon-lambda, Ribavirin, Daclatasvir
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Chicago, Illinois • Philadelphia, Pennsylvania + 1 more
- Conditions
- Hepatitis C
- Interventions
- BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- San Clemente, California • Worcester, Massachusetts • Providence, Rhode Island + 1 more
- Conditions
- Hepatitis C Virus Genotype-1
- Interventions
- TMC435, Pegylated interferon alpha-2a, Ribavirin
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more
- Conditions
- Hepatitis C Infection
- Interventions
- Placebo, SCY-635, Pegasys, Copegus
- Drug
- Lead sponsor
- Scynexis, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- San Francisco, California • Durham, North Carolina • San Antonio, Texas
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Sorafenib (Nexavar, BAY43-9006), Interferon
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 9
- States / cities
- Sacramento, California • Aurora, Colorado • Chicago, Illinois + 6 more
- Conditions
- Hepatitis C Virus
- Interventions
- Asunaprevir (ASV), Daclatasvir (DCV), Pegylated-interferon alfa 2a (PegIFN), Ribavirin (RBV)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 748 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 18
- States / cities
- Montgomery, Alabama • La Jolla, California • Los Angeles, California + 14 more
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- Pegylated interferon lambda (pegIFNλ), Pegylated interferon alfa-2a (pegIFNα-2a), Ribavirin, Daclatasvir, Placebo matching Daclatasvir
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • San Diego, California • San Francisco, California + 12 more
- Conditions
- Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma
- Interventions
- Cemiplimab-Rwlc, PEG-IFN alfa-2a
- Drug
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hepatitis C
- Interventions
- Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Immunosuppressant Regimen
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
- Conditions
- High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
- Interventions
- PEGASYS, Hydroxyurea, Aspirin
- Drug
- Lead sponsor
- Ronald Hoffman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 10 more
- Conditions
- Chronic Myelogenous Leukemia
- Interventions
- imatinib mesilate, interferon-alpha (INF-a), cytarabine (ARA-C)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2012
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 50 more
- Conditions
- Breast Cancer, Metastatic Cancer
- Interventions
- PEG-interferon alfa-2a, Capecitabine
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 4
- States / cities
- Wichita, Kansas • Grand Rapids, Michigan • Springfield, Missouri + 1 more
- Conditions
- Chronic Hepatitis C Infection, Fatty Liver
- Interventions
- Rosiglitazone and Pegasys/Ribavirin
- Drug
- Lead sponsor
- Beth Israel Medical Center
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV Infections, Hepatitis C
- Interventions
- Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 24
- States / cities
- San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- Hepatitis C
- Interventions
- INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Anaheim, California • La Jolla, California • San Francisco, California + 3 more
- Conditions
- Ovarian Cancer
- Interventions
- Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure
- Drug · Biological · Procedure
- Lead sponsor
- Kalinski, Pawel, MD, PhD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Leukemia
- Interventions
- Recombinant Interferon Alfa, Cytarabine, Omacetaxine Mepesuccinate
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV Infections, Hepatitis C, Hemophilia
- Interventions
- Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 15 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Genotype 1 Chronic Hepatitis C
- Interventions
- GI-5005, Pegylated Interferon and Ribavirin
- Drug
- Lead sponsor
- GlobeImmune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more
- Conditions
- Chronic Hepatitis C
- Interventions
- GS-5885, GS-9451, RBV, PEG
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 20 more
- Conditions
- Hepatitis C
- Interventions
- peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 8
- States / cities
- San Francisco, California • Miami, Florida • Chicago, Illinois + 5 more
- Conditions
- Polycythemia Vera, Essential Thrombocythemia
- Interventions
- RG7388, Pegasys
- Drug
- Lead sponsor
- John Mascarenhas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • New York, New York • Winston-Salem, North Carolina